|
市場調査レポート
患者ケアの改善およびコスト削減戦略
Beyond Disease Management: Strategies for Improving Patient Care and Cutting Costs
|
当商品の販売は、2011年12月21日を持ちまして終了しました。
Abstract
Introduction
Disease management has become a common term in the U.S. health care system.
Yet, the more widely the term has been adopted, the more diffuse the defi
nition of this health care strategy has become. Whatever the actual defi
nition, many employers regard cost-containment as a key objective of DM
initiatives. DM activity is focused largely on several highly prevalent
chronic disorders-diabetes, asthma, hypertension, and dyslipidemia.
Manufacturers of therapies need to prepare for the impact of DM on these
markets.
Get the Answers You Need to Shape Your Strategy
- A 2006 survey found that 76% of employers saw a connection between
employees' health status and employees' productivity. How can
pharmaceutical companies underscore the positive impact of good health on
productivity?
- The most basic challenge in recruiting participants for any form of care
management program is identifying suitable candidates for enrollment. How
do health plans stratify patients into risk categories? How do they use this
information to project health care costs for patients?
- Disease management programs will likely alter established prescribing
patterns. What effects will these programs have on drug sales? Which
classes will be most affected?
- For most employers, cost-containment is an essential objective of care
management. How do companies rate the effectiveness of these plans as a
cost-cutting measure?
Scope
- Disease management overview: defi nition and evolution of disease
management and related strategies.
- Employers' views on disease management: fi ndings from an employer
health benefi t survey.
- Challenges of patient enrollment: identifying candidates,
persuading members to sign up for the program, whether to offer incentives to
employees.
- Disease management in Medicare: how to apply the DM concept to
Medicare benefi ciaries.
- State initiative: several state governments have begun to explore
the potential of DM.
- Outlook: implications of disease management for the pharmaceutical
industry.
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Evolution of Disease Management and Related Strategies
- Growing Demand for Disease Management and Related Strategies
- Challenges of Patient Enrollment
- Employers' Views on Disease Management
- Medicare Initiatives
- Medicaid and State Initiatives
- Support from CMS
- State Initiatives
- Outlook and Implications for the Pharmaceutical Industry
Sidebars
- What Is Disease Management?
- Florida Gives Manufacturer-Sponsored Disease Management Programs a Second
Chance
Tables
- 1. U.S. Employers' Actual and Potential Use of Select Care Management
Measures
- 2. Pharmaceutical Manufacturer-Sponsored Disease Management Programs
Certified by the National Committee for Quality Assurance, November 2007
Figures
- 1. Percentage of U.S. Employers of Various Sizes That Offer Health Benefi
ts and Disease Management Programs, 2006
- 2. Coverage of Key Indications in U.S. Employers' Disease Management
Programs, 2006
- 3. Coverage of Select Indications in Disease Management Programs of Health
Maintenance Organizations That Offer Disease Management, 2006
- 4. U.S. Employers' Perceptions of the Effectiveness of Disease Management
as a Cost-Containment Measure, 2007
|
